Prion Biotech 2018 Neurological Disorders Treatment Presentation

Prion Biotech presents its clinical development strategy for first-in-class neurological therapies, focusing on PBT434, a novel small-molecule compound designed to inhibit iron-mediated alpha-synuclein accumulation in Parkinson's disease. The company, established in 1997 and listed on both ASX and Nasdaq, leverages a library of over 2,000 therapeutic candidates and prior experience in neurodegenerative disease programs.